TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/16/2026
Back to search
Official data from USPTO
DAY ONE BIOPHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
07/17/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 36, 41, 42
Filing date
09/21/2023
Registration date
03/24/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/24/2026
Last transaction
07/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/23/2024
First use in commerce
04/23/2024
Drawing code
3
Owner type
03
Owner location
Brisbane, CA, US
Examiner
I, DAVID C
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the words DAY ONE above the word BIOPHARMACEUTICALS with sun rays emanating from and above the "e" at the end of the word ONE.
Holders and representatives
Holders
Day One Biopharmaceuticals, Inc.
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 5Class 36Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for treating cancer and oncological diseases; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of oncologicalneurologicalimmune system related diseases and disorders; medical preparations for the delivery of compounds to the body for the treatment and prevention of oncologicalneurologicalimmune system related diseases and disorders
Class 36
Healthcare insurance administration services; healthcare insurance administration servicesproviding benefit verificationauthorization and re-authorization supportappeals supportinformation regarding benefit updates; providing information about healthcare insurance plans; financial servicesassessing sources of and facilitating access by patients and their families to financial support from copay supportpatient assistance programs (PAP)patient foundations and organizations; financial servicesadministration of patient reimbursement programs
Class 41
Educational servicesproviding online newsletters in the field of prescription drug information via emailsnon-downloadable webinarsonline non-downloadable videos in the field of prescription drug information; educational servicesproviding prescription drug dosage training; educational servicesproviding online non-downloadable videos in the field of treatment and diagnosis of tumors and cancer; educational servicesproviding online non-downloadable videos in the field of treatment and diagnosis of pediatric low-grade glioma; educational servicesproviding online non-downloadable videos for healthcare service providerscaregiverspatients in the field of tumors and cancer; educational servicesproviding online non-downloadable videos for healthcare service providerscaregiverspatients in the field of pediatric low-grade glioma; providing information regarding tumors and cancerpediatric low-grade glioma
Class 42
Researchdevelopmentproduct evaluation of pharmaceutical preparations for the prevention and treatment of cancer; research laboratory analysis and research of drugs and pharmaceutical products; providing medical research information in the fields of oncologyimmunotherapychemotherapy and combination therapies; research and development services in the fields of oncologyimmunotherapychemotherapycombination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncologyimmunotherapychemotherapy and combination therapies; scientific advisory servicesproviding scientific informationadviceconsultancy in the field of cancer treatment; designdevelopmentresearchtesting of new productsdrugs and pharmaceuticals for the treatment and/or prevention of oncologicalneurologicalimmune system diseases and disorders; researchdevelopmentmedical evaluation of pharmaceutical preparations for the prevention and treatment of cancer; research and development services in the fields of oncologyimmunotherapychemotherapycombination therapies for the treatment of cancer and tumors; scientific advisory servicesproviding scientific informationadviceconsultancy in the field of cancer treatment; designdevelopmentresearchtesting of drugs and pharmaceuticals for the treatment and/or prevention of oncologicalneurologicalimmune system related diseases and disorders
Publications
History of USPTO decisions and trademark events.
42 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/16/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/16/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/16/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/16/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/24/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/24/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/04/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/04/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/08/2026
IUAF
USE AMENDMENT FILED
01/13/2026
EISU
TEAS STATEMENT OF USE RECEIVED
01/13/2026
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/15/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/20/2025
PUBO
PUBLISHED FOR OPPOSITION
05/20/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/14/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/21/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/09/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/09/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/10/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/10/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/10/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/10/2025
GNFR
FINAL REFUSAL E-MAILED
01/10/2025
CNFR
FINAL REFUSAL WRITTEN
01/10/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
10/15/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/10/2024
DRRR
DIVISIONAL REQUEST RECEIVED
09/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/09/2024
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
09/09/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
06/06/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
06/06/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/08/2024
GNRT
NON-FINAL ACTION E-MAILED
03/08/2024
CNRT
NON-FINAL ACTION WRITTEN
03/08/2024
DOCK
ASSIGNED TO EXAMINER
02/27/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/09/2023
NWAP
NEW APPLICATION ENTERED
09/25/2023
Continuous trademark protection
Get notified about every new filing that threatens DAY ONE BIOPHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.